Constellation Pharmaceuticals has formed a major epigenetics collaboration with Roche’s Genentech unit that provides the biotech with committed funding of US$95 M. The partnership spans multiple epigenetic target classes, but does not include Constellation’s two most advanced programmes focused on the development of inhibitors of the BET chromatin reader and EZH2 chromatin writer proteins. The agreement provides Genentech with a future option to acquire Constellation based on prenegotiated terms.